Comparative Pharmacology
Head-to-head clinical analysis: RELA versus ROBAXIN 750.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RELA versus ROBAXIN 750.
RELA vs ROBAXIN-750
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
RELA (Carisoprodol) is a centrally acting muscle relaxant that modulates GABA-A receptor activity and blocks interneuronal activity in the descending reticular formation and spinal cord, resulting in muscle relaxation without directly affecting the neuromuscular junction. Its metabolite, meprobamate, contributes to anxiolytic and sedative effects.
Methocarbamol, the active ingredient in Robaxin-750, is a centrally acting muscle relaxant. Its precise mechanism is not fully understood, but it is believed to cause general central nervous system depression, possibly through inhibition of polysynaptic reflexes at the spinal cord level.
Adults: 250-350 mg orally 3-4 times daily.
750 mg orally four times daily (total daily dose 3000 mg).
None Documented
None Documented
Terminal elimination half-life approximately 20–30 hours; prolonged in elderly and renal impairment
Terminal elimination half-life: 1-2 hours (methocarbamol); clinical context: short half-life necessitates frequent dosing (q6h) and may lead to fluctuating plasma levels.
Primarily renal excretion of unchanged drug and metabolites; 70% to 80% eliminated via urine, remainder biliary/fecal
Renal: 90-95% as metabolites (mainly conjugated), <1% unchanged; biliary/fecal: minor; <2% eliminated in feces.
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant